Syncona Ltd
LSE:SYNC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Levi Strauss & Co
NYSE:LEVI
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0.6), the stock would be worth GBX105.78 (20% upside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 0.5 | GBX87.9 |
0%
|
| 3-Year Average | 0.6 | GBX105.78 |
+20%
|
| 5-Year Average | 0.8 | GBX132.79 |
+51%
|
| Industry Average | 0 | GBX1.28 |
-99%
|
| Country Average | 0 | GBX2.12 |
-98%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| GG |
|
Syncona Ltd
LSE:SYNC
|
534.3m GBP | 0.5 | -5.7 | |
| US |
G
|
GE Vernova LLC
NYSE:GEV
|
303.9B USD | 0 | 0 | |
| UK |
E
|
Eight Capital Partners PLC
F:ECS
|
158.4B EUR | 0 | 0 | |
| US |
C
|
China Industrial Group Inc
OTC:CIND
|
121B USD | 1 319.4 | 4 020.7 | |
| NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
102.7B ZAR | 1.1 | 10.6 | |
| US |
F
|
Fintech Ecosystem Development Corp
NASDAQ:FEXD
|
68.1B USD | 1 963.7 | 38 496.8 | |
| US |
C
|
CoreWeave Inc
NASDAQ:CRWV
|
61.5B USD | 0 | 0 | |
| CH |
G
|
Galderma Group AG
SIX:GALD
|
35.8B CHF | 0 | 0 | |
| US |
|
Coupang Inc
F:788
|
33.1B EUR | 7.9 | 175.5 | |
| US |
|
Symbotic Inc
NASDAQ:SYM
|
38.1B USD | 57.2 | -3 496.4 | |
| ZA |
V
|
Vukile Property Fund Ltd
JSE:VKE
|
30.2B ZAR | 1 | 7 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0.8 |
| Max | 5.8 |
Other Multiples
Syncona Ltd
Glance View
Syncona Ltd is a GG-based company operating in industry. Syncona Limited is a Guernsey-based closed-ended investment company. The firm is a healthcare company focused on founding, building and funding a portfolio of life science companies. The Company’s investment objective is to achieve superior long-term capital appreciation from its investments. The firm invests in life science businesses (including private and quoted companies) and single or multi-asset projects (Life Science Investments). Syncona Investment Management Limited (SIML), acts as the Company’s alternative investment fund manager (investment manager).
